NASDAQ: $DFTX New Hope for Migraine Sufferers Definium Therapeutics has recently announced significant progress in the treatment of migraine attacks. The company released positive topline results from their Phase 3 PANORAMA study, which evaluated the efficacy and safety of DT-120 ODT, an orally disintegrating tablet designed for the acute treatment of migraine. Understanding the PANORAMA…